Updating results

99 results

Sort: Relevance | Date

Inotersen for treating hereditary transthyretin amyloidosis (HST9)

Evidence-based recommendations on inotersen (Tegsedi) for stage 1 and stage 2 polyneuropathy in adults with hereditary transthyretin amyloidosis

Highly specialised technologies guidance Published May 2019

Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 (HST12)

Evidence-based recommendations on cerliponase alfa (Brineura) for treating neuronal ceroid lipofuscinosis type 2 in children

Highly specialised technologies guidance Published November 2019

Voretigene neparvovec for treating inherited retinal dystrophies caused by RPE65 gene mutations (HST11)

Evidence-based recommendations on voretigene neparvovec (Luxturna) for RPE65-mediated inherited retinal dystrophies in people with vision loss caused by inherit

Highly specialised technologies guidance Published October 2019

Patisiran for treating hereditary transthyretin amyloidosis (HST10)

Evidence-based recommendations on patisiran (Onpattro) for treating hereditary transthyretin amyloidosis in adults with stage 1 and stage 2 polyneuropathy

Highly specialised technologies guidance Published August 2019

Balloon dilation for chronic eustachian tube dysfunction (IPG665)

Evidence-based recommendations on balloon dilation for chronic eustachian tube dysfunction in adults and children

Interventional procedures guidance Published December 2019

Irreversible electroporation for primary liver cancer (IPG664)

Evidence-based recommendations on irreversible electroporation for primary liver cancer in adults

Interventional procedures guidance Published November 2019

Midcarpal hemiarthroplasty for wrist arthritis (IPG663)

Evidence-based recommendations on midcarpal hemiarthroplasty (using a metal implant to create an artificial wrist joint) for wrist arthritis in adults

Interventional procedures guidance Published October 2019

Implant insertion for prominent ears (IPG660)

Evidence-based recommendations on implant insertion for prominent ears in children, young people and adults

Interventional procedures guidance Published September 2019

Reinforcement of a permanent stoma with a synthetic or biological mesh to prevent a parastomal hernia (IPG654)

Evidence-based recommendations on reinforcement of a permanent stoma with a synthetic or biological mesh to prevent a parastomal hernia

Interventional procedures guidance Published June 2019

Valve-in-valve TAVI for aortic bioprosthetic valve dysfunction (IPG653)

Evidence-based recommendations on valve-in-valve transcatheter aortic valve implantation (ViV-TAVI) for aortic bioprosthetic valve dysfunction in adults

Interventional procedures guidance Published June 2019

Bronchoscopic thermal vapour ablation for upper-lobe emphysema (IPG652)

Evidence-based recommendations on bronchoscopic thermal vapour ablation for upper-lobe emphysema in adults

Interventional procedures guidance Published June 2019

Percutaneous mechanical thrombectomy for acute deep vein thrombosis of the leg (IPG651)

Evidence-based recommendations on percutaneous mechanical thrombectomy for acute deep vein thrombosis (DVT) of the leg in adults

Interventional procedures guidance Published June 2019

Percutaneous insertion of a cerebral protection device to prevent cerebral embolism during TAVI (IPG650)

Evidence-based recommendations on percutaneous insertion of a cerebral protection device to prevent cerebral embolism during TAVI (transcatheter aortic valve

Interventional procedures guidance Published June 2019

Percutaneous mitral valve leaflet repair for mitral regurgitation (IPG649)

Evidence-based recommendations on percutaneous mitral valve leaflet repair for mitral regurgitation in adults

Interventional procedures guidance Published May 2019

Reducing the risk of transmission of Creutzfeldt–Jakob disease (CJD) from surgical instruments used for interventional procedures on high-risk tissues (IPG666)

Evidence-based recommendations on reducing the risk of Creutzfeldt–Jakob disease (CJD) transmission from surgical instruments used for interventional procedures

Interventional procedures guidance Published January 2020

Therapeutic hypothermia for acute ischaemic stroke (IPG647)

Evidence-based recommendations on therapeutic hypothermia (using a cooling device to reduce the body’s temperature) for acute ischaemic stroke in adults

Interventional procedures guidance Published May 2019

Endoscopic ablation for a pilonidal sinus (IPG646)

Evidence-based recommendations on endoscopic ablation for a pilonidal sinus in adults

Interventional procedures guidance Published April 2019

Endoscopic ablation for an anal fistula (IPG645)

Evidence-based recommendations on endoscopic ablation for an anal fistula in adults

Interventional procedures guidance Published April 2019

Radially emitting laser fibre treatment of an anal fistula (IPG644)

Evidence-based recommendations on radially emitting laser fibre treatment of an anal fistula in adults

Interventional procedures guidance Published March 2019

High-intensity focused ultrasound for symptomatic benign thyroid nodules (IPG643)

Evidence-based recommendations on high-intensity focused ultrasound for symptomatic benign thyroid nodules in adults

Interventional procedures guidance Published February 2019

Barnett Continent Intestinal Reservoir (modified continent ileostomy) to restore continence after colon and rectum removal (IPG642)

Evidence-based recommendations on Barnett Continent Intestinal Reservoir (modified continent ileostomy) to restore continence after colon and rectum removal

Interventional procedures guidance Published February 2019

Ultrasound-guided high-intensity transcutaneous focused ultrasound for symptomatic uterine fibroids (IPG657)

Evidence-based recommendations on ultrasound-guided high-intensity transcutaneous focused ultrasound for symptomatic uterine fibroids in adults

Interventional procedures guidance Published July 2019

Transurethral laser ablation for recurrent non-muscle-invasive bladder cancer (IPG656)

Evidence-based recommendations on transurethral laser ablation for recurrent non-muscle-invasive bladder cancer in adults

Interventional procedures guidance Published July 2019

Cardiac contractility modulation device implantation for heart failure (IPG655)

Evidence-based recommendations on cardiac contractility modulation device implantation for heart failure in adults

Interventional procedures guidance Published June 2019

Fetoscopic prenatal repair for open neural tube defects in the fetus (IPG667)

Evidence-based recommendations on fetoscopic prenatal repair of open neural tube defects in the fetus

Interventional procedures guidance Published January 2020

Open prenatal repair for open neural tube defects in the fetus (IPG668)

Evidence-based recommendations on open prenatal repair of open neural tube defects in the fetus

Interventional procedures guidance Published January 2020

Collagen paste for closing an anal fistula (IPG648)

Evidence-based recommendations on collagen paste for closing an anal fistula in adults

Interventional procedures guidance Published May 2019

High-intensity focused ultrasound for glaucoma (IPG661)

Evidence-based recommendations on high-intensity focused ultrasound for glaucoma in adults. This involves using high-intensity ultrasound to destroy a small

Interventional procedures guidance Published September 2019

Bioprosthetic plug insertion for anal fistula (IPG662)

Evidence-based recommendations on bioprosthetic plug insertion for anal fistula in adults. This involves putting a plug into the fistula and stitching it in

Interventional procedures guidance Published September 2019

Endovascular insertion of an intrasaccular wire-mesh blood-flow disruption device for intracranial aneurysms (IPG658)

Evidence-based recommendations on endovascular insertion of an intrasaccular wire-mesh blood-flow disruption device for intracranial aneurysms in adults. This

Interventional procedures guidance Published August 2019

Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality (TA322)

Evidence-based recommendations on lenalidomide (Revlimid) for myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality

Technology appraisal guidance Published September 2014 Last updated June 2019

Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure (TA617)

Evidence-based recommendations on lusutrombopag (Mulpleo) for severe thrombocytopenia in adults with chronic liver disease needing a planned invasive procedure

Technology appraisal guidance Published January 2020

Atezolizumab with carboplatin and nab-paclitaxel for untreated advanced non-squamous non-small-cell lung cancer (terminated appraisal) (TA618)

NICE is unable to make a recommendation about the use in the NHS of atezolizumab (Tecentriq) with carboplatin and nab-paclitaxel for untreated advanced NSCLC

Technology appraisal guidance Published January 2020

Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer (TA619)

Evidence-based recommendations on palbociclib (Ibrance) with fulvestrant for hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer

Technology appraisal guidance Published January 2020

Olaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer (TA620)

Evidence-based recommendations on olaparib (Lynparza) for relapsed platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer in adults with a

Technology appraisal guidance Published January 2020

Ramucirumab for treating unresectable hepatocellular carcinoma after sorafenib (terminated appraisal) (TA609)

NICE is unable to make a recommendation about the use in the NHS of ramucirumab (Cyramza) for treating unresectable hepatocellular carcinoma after sorafenib

Technology appraisal guidance Published October 2019

Ibrutinib with rituximab for treating Waldenstrom's macroglobulinaemia (terminated appraisal) (TA608)

NICE is unable to make a recommendation about the use in the NHS of ibrutinib (Imbruvica) with rituximab for treating Waldenstrom’s macroglobulinaemia in adults

Technology appraisal guidance Published October 2019

Lanadelumab for preventing recurrent attacks of hereditary angioedema (TA606)

Evidence-based recommendations on lanadelumab (Takhzyro) for preventing recurrent attacks of hereditary angioedema in people aged 12 and over

Technology appraisal guidance Published October 2019

Lenalidomide with bortezomib and dexamethasone for untreated multiple myeloma (terminated appraisal) (TA603)

NICE is unable to make a recommendation about the use in the NHS of lenalidomide (Revlimid) with bortezomib and dexamethasone for untreated multiple myeloma

Technology appraisal guidance Published September 2019

Pomalidomide with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) (TA602)

NICE is unable to make a recommendation about the use in the NHS of pomalidomide (Imnovid) with bortezomib and dexamethasone for relapsed or refractory myeloma

Technology appraisal guidance Published September 2019

Bezlotoxumab for preventing recurrent Clostridium difficile infection (terminated appraisal) (TA601)

NICE is unable to make a recommendation about the use in the NHS of bezlotoxumab (Zinplava) for preventing recurrent Clostridium difficile infection in adults

Technology appraisal guidance Published September 2019

Brentuximab vedotin for untreated advanced Hodgkin lymphoma (terminated appraisal) (TA594)

NICE is unable to make a recommendation about the use in the NHS of brentuximab vedotin (Adcetris) for untreated advanced Hodgkin lymphoma in adults

Technology appraisal guidance Published August 2019

Patiromer for treating hyperkalaemia (TA623)

Evidence based recommendations on patiromer (Veltassa) for treating hyperkalaemia in adults

Technology appraisal guidance Published February 2020

Cabozantinib for previously treated advanced hepatocellular carcinoma (terminated appraisal) (TA582)

NICE is unable to make a recommendation about the use in the NHS of cabozantinib (Cometriq) for previously treated advanced hepatocellular carcinoma in adults

Technology appraisal guidance Published May 2019

Bosutinib for untreated chronic myeloid leukaemia (terminated appraisal) (TA576)

NICE is unable to make a recommendation about the use in the NHS of bosutinib for untreated chronic myeloid leukaemia because no evidence submission was

Technology appraisal guidance Published April 2019

Lenalidomide for the treatment of multiple myeloma in people who have received at least 2 prior therapies (TA171)

Evidence-based recommendations on lenalidomide (Revlimid) for the treatment of multiple myeloma in people who have received at least 2 prior therapies

Technology appraisal guidance Published June 2009 Last updated June 2019

Pembrolizumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy (terminated appraisal) (TA570)

NICE is unable to make a recommendation about the use in the NHS of pembrolizumab (Keytruda) for treating recurrent or metastatic squamous cell carcinoma of the

Technology appraisal guidance Published March 2019

Abatacept for treating psoriatic arthritis after DMARDs (terminated appraisal) (TA568)

NICE is unable to make a recommendation on abatacept (Orencia) for treating psoriatic arthritis after DMARDs in adults because of no evidence submission from

Technology appraisal guidance Published March 2019

Dabrafenib with trametinib for treating advanced metastatic BRAF V600E mutation-positive non-small-cell lung cancer (terminated appraisal) (TA564)

NICE is unable to make a recommendation about the use in the NHS of dabrafenib with trametinib for treating advanced metastatic BRAF V600E mutation-positive

Technology appraisal guidance Published February 2019

Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer (TA621)

Evidence-based recommendations on osimertinib (Tagrisso) for untreated locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (NSCLC)

Technology appraisal guidance Published January 2020